Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc. (ORIC)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -35,767 | -30,505 | -98,963 | NaN |
| Depreciation | 270 | 320 | 900 | NaN |
| Stock-based compensation expense | 6,898 | 6,278 | 18,759 | NaN |
| Amortization of premium (accretion of discount) on investments, net | -162 | 240 | 2,060 | NaN |
| Prepaid expenses and other assets | 679 | -2,112 | 325 | NaN |
| Accounts payable and accrued other liabilities | -3,322 | -448 | -6,798 | NaN |
| Net cash used in operating activities | -32,438 | -22,483 | -88,487 | NaN |
| Acquisitions of property and equipment | 2 | 227 | 485 | NaN |
| Purchases of investments | 77,973 | 45,289 | 354,530 | NaN |
| Maturities of investments | 60,000 | 62,500 | 190,000 | NaN |
| Net cash (used in) provided by investing activities | -17,975 | 16,984 | -165,015 | NaN |
| Proceeds from issuance of common stock | 60,881 | 0 | 244,369 | NaN |
| Issuance costs associated with financings | 993 | 0 | 2,397 | NaN |
| Proceeds from issuance of common stock under espp | NaN | 556 | 757 | NaN |
| Proceeds from stock option exercises | 1,252 | 944 | 1,035 | NaN |
| Net cash provided by financing activities | 61,140 | 1,500 | 243,764 | NaN |
| Restricted cash and cash equivalents | NaN | NaN | NaN | 491 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 10,727 | -3,999 | -9,738 | NaN |
| Cash and cash equivalents, at carrying value, ending balance | NaN | NaN | NaN | 75,864 |
| Cash, cash equivalents and restricted cash at beginning of period | 46,160 | 50,159 | 76,355 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 56,887 | 46,160 | 50,159 | 76,355 |